Jane Pritchett Henderson's most recent trade in Apogee Therapeutics Inc. was a trade of 1,108 Common Stock done at an average price of $66.1 . Disclosure was reported to the exchange on Feb. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 66.15 per share. | 02 Feb 2026 | 1,108 | 183,471 | - | 66.1 | 73,294 | Common Stock |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 65.21 per share. | 02 Feb 2026 | 792 | 184,579 | - | 65.2 | 51,646 | Common Stock |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 66.89 per share. | 02 Feb 2026 | 100 | 183,371 | - | 66.9 | 6,689 | Common Stock |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 83,690 | 83,690 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 75.20 per share. | 02 Jan 2026 | 4,080 | 187,371 | - | 75.2 | 306,816 | Common Stock |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 02 Jan 2026 | 2,000 | 185,371 | - | 80 | 160,000 | Common Stock |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 74.13 per share. | 02 Jan 2026 | 1,920 | 191,451 | - | 74.1 | 142,330 | Common Stock |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 19 Dec 2025 | 1,500 | 193,371 | - | 80 | 120,000 | Common Stock |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 04 Dec 2025 | 1,500 | 194,871 | - | 75 | 112,500 | Common Stock |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 25 Nov 2025 | 1,500 | 196,371 | - | 70 | 105,000 | Common Stock |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 14 Nov 2025 | 2,000 | 197,871 | - | 65 | 130,000 | Common Stock |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 11 Nov 2025 | 1,000 | 199,871 | - | 60 | 60,000 | Common Stock |
| CARGO Therapeutics Inc | Jane Pritchett Henderson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Aug 2025 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Sale of securities on an exchange or to another person at price $ 47.46 per share. | 12 Aug 2025 | 3,000 | 9,398 (0%) | 0% | 47.5 | 142,371 | Common Stock |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2025 | 3,000 | 11,797 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.01 per share. | 12 Aug 2025 | 3,000 | 12,398 (0%) | 0% | 7.0 | 21,027 | Common Stock |
| CARGO Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 9,398 | 9,398 (0%) | 0% | 0 | Common Stock | |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 124,962 | 124,962 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.26 per share. | 23 Aug 2024 | 6,000 | 200,871 | - | 48.3 | 289,560 | Common Stock |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2024 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| CARGO Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 39,402 | 39,402 | - | - | Stock Option (Right to Buy) | |
| CARGO Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 19,785 | 19,785 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Henderson Pritchett Jane | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 175,345 | 175,345 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.01 per share. | 16 Jun 2023 | 40,000 | 40,000 (0%) | 0% | 7.0 | 280,400 | Common Stock |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 40,000 | 14,797 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Sale of securities on an exchange or to another person at price $ 54.46 per share. | 16 Jun 2023 | 22,498 | 0 (0%) | 0% | 54.5 | 1,225,291 | Common Stock |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Sale of securities on an exchange or to another person at price $ 53.79 per share. | 16 Jun 2023 | 17,502 | 22,498 (0%) | 0% | 53.8 | 941,394 | Common Stock |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Invivyd Inc | Jane Pritchett Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2022 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) |